H.I.G. Capital – a leading global alternative investment firm with $65 billion of capital under management – announced that one of its affiliates has completed the acquisition of SkinCure Oncology Intermediate, a leading provider of image-guided superficial radiation therapy (IG-SRT) solutions.
SkinCure Oncology’s executive team (led by CEO Kerwin Brandt) will continue to lead the Company and remain significant shareholders.
Based in Burr Ridge, IL, SkinCure Oncology provides its physician partners with a comprehensive model for the delivery of IG-SRT for the treatment of nonmelanoma skin cancer. Compared to traditional surgical methods, IG-SRT involves no cutting or need for reconstructive surgery. This enables patients to maintain normal activities throughout treatment while offering cosmetic benefits for those concerned about surgical scarring. Presented to patients as The GentleCure Experience, IG-SRT is available from over 500 physicians nationwide and more than 100,000 patients have been treated with the technology.
KEY QUOTES:
“We are excited to work with H.I.G. and believe this partnership will help us continue executing on our growth strategy and vision for the Company. This includes expanding the availability of our GentleCure™ platform across both existing and new dermatology and Mohs practice partners, while maintaining the Company’s entrepreneurial culture and dedication to our partners and employees that have defined SkinCure since 2016.”
-Kerwin Brandt
“We are thrilled to partner with Kerwin and the SkinCure Oncology team. There are tremendous opportunities ahead for the Company, given its strong track record of delivering outstanding outcomes for both its physician partners and their patients. The Company has established itself as a leader in the industry, and we look forward to supporting their continued expansion to ensure increased options and access to care for patients with nonmelanoma skin cancer.”
-Scott Zhu, Managing Director at H.I.G.
